Lotus Tissue Repair Scores $26 Million in Series A Round
This article was originally published in The Pink Sheet Daily
Rare disease start-up scores Series A financing and technology patents to develop a treatment for a deadly genetic disorder.
You may also be interested in...
Third Rock Ventures has raised $1.3 billion by going all-in on early-stage biotech with a homegrown company strategy that requires that its own people run many of its portfolio companies after launch. It’s hard to say definitively that the strategy is working, but then again, its investors just re-upped for a new half-billion-dollar fund.
The early-stage biotech venture firm drew its largest fund yet, topping $1 billion raised since inception, despite notching only two exits from its first two funds.
The biotech venture firm continues to draw investors despite lacking a large number of exits for its portfolio companies. Its third fund brought in the largest investment yet for the firm.